The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > BUSINESS
BUSINESS
- Ribomic Ready to Out-License Aptamer-Based Drug RBM007
October 21, 2014
- GSK, Sumitomo Dainippon to Wind Up Paxil Copromotion at Year-End
October 21, 2014
- Nippon Boehringer Ingelheim Seeks Japan Approval for Nintedanib
October 21, 2014
- Alexion Submits NDA for Hypophosphatasia Treatment Asfotase Alfa
October 20, 2014
- Seikagaku Establishes Representative Office in US
October 20, 2014
- Astellas to End License Agreement with US Venture Company for AD Treatments
October 20, 2014
- AMO Japan Appoints Shoko Suzuki of Coca-Cola Japan as New President
October 20, 2014
- Takeda, euglena Strike Comprehensive Collaboration Deal for Euglena-Containing Product Development
October 20, 2014
- Bayer AG Aims to Achieve Japan Sales of 300 Billion Yen by 2017
October 17, 2014
- Bayer HealthCare Signs Two-Year Collaborative Search Activity Agreement with Kyoto Univ.
October 17, 2014
- FDA Gives Priority Review Status to Lenvatinib, Rufinamide: Eisai
October 17, 2014
- Pfizer Japan Voluntarily Recalls Torisel Due to Microparticles in Diluent
October 17, 2014
- EPS to Take Full Control of EP-Mint in January
October 16, 2014
- Mochida Hooks Up with LG Life Sciences on Adalimumab Biosimilar
October 16, 2014
- Daiichi Sankyo Launches Tender Offer for US Biotech Ambit
October 16, 2014
- FDA OKs World’s 1st Oral Combination Drug for CINV: Helsinn, Eisai
October 16, 2014
- Astellas, Harvard Conduct Joint Research for Retinitis Pigmentosa
October 16, 2014
- Kyorin Licenses Uritos to R-Pharm of Russia
October 15, 2014
- Parexel CEO Hails Rise of Partnership-Based Outsourcing in Japan
October 14, 2014
- Fujifilm’s Overseas Subsidiaries Develop High-Performance Mammalian Expression Platform
October 14, 2014
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…